Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27344645 | 0.90 | KIF11 (0.63) | KIF11KDM4EKDM1AMAOBKMT2A | |
| SCHEMBL1765328 | 0.89 | KIF11 (0.59) | KIF11NPC1RAB9ASMN1; SMN2GFER | |
| SCHEMBL29690424 | 0.88 | KIF11 (0.61) | KIF11KDM4EKDM1AMAOBKMT2A | |
| SCHEMBL28530523 | 0.88 | KIF11 (0.61) | KIF11KDM4EKDM1AMAOBKMT2A | |
| SCHEMBL4342508 | 0.86 | KIF11 (0.59) | KIF11KDM4EKDM1AMAOBKMT2A | |
| SCHEMBL556994 | 0.83 | KIF11 (0.56) | KIF11NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL3392514 | 0.81 | KIF11 (0.55) | KIF11KDM4EKDM1AMAOBKMT2A | |
| SCHEMBL28403735 | 0.81 | KIF11 (0.55) | KIF11NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL29164328 | 0.81 | KIF11 (0.55) | KIF11KDM4EALDH1A1KDM1AMAOB | |
| SCHEMBL8192167 | 0.81 | KIF11 (0.55) | KIF11KDM4EALDH1A1POLBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322826-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322826-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-10-12 | — | — | US | disclosed |
| US-11713332-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| US-11713332-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| US-11031562-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| EP-3484868-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2020-11-25 | — | — | EP | disclosed |
| EP-3484868-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2020-11-25 | — | — | EP | disclosed |
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190315787-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| WO-2018011186-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2018-01-18 | — | — | WO | disclosed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| CN-1968921-A | Glucagon receptor antagonists, preparation and therapeutic uses | LILLY CO ELI (US) | 2007-05-23 | — | — | CN | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315787-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | KIF11 1971/4885NPC1 3533/4885RAB9A 2231/4885 |
| US-11031562-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | KIF11 1598/4885NPC1 3647/4885RAB9A 2094/4885 |
| US-11713332-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | KIF11 1971/4885NPC1 3533/4885RAB9A 2231/4885 |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | KIF11 4170/4885NPC1 2178/4885RAB9A 1771/4885 |
| US-20230322826-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | KIF11 1971/4885NPC1 3533/4885RAB9A 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.